Vaccinia virus growth in BSC-1 and HeLa cells was inhibited by aphidicolin concentrations of 20 puM or more. Virus yield, which decreased only when the drug was added early in infection, was reduced several 100-fold by 80 tLM aphidicolin. Viral inhibition was reversed by the suspension of the infected cells in drug-free medium. DNA synthesis in uninfected cells was reduced about 10-fold by 1 ,uM aphidicolin. In infected cells, aphidicolin concentrations over 10 ,uM were needed to reduce DNA synthesis to the same extent as in uninfected cells. Fractionation of infected cells which were incubated with 1 ,uM drug showed that cytoplasmic viral DNA synthesis was resistant to this aphidicolin concentration. The radioactivity associated with crude nuclei from these cells was estimated to be from vaccinia DNA synthesis. Spontaneous virus mutants which were resistant to 80 ,uM aphidicolin did not appear. However, after mutagenesis, mutants were generated which formed large plaques in medium with 80 ,uM drug. In cells with replicating aphidicolin-resistant virus, DNA synthesis was about four times more resistant to 80 ,uM aphidicolin than in cells with replicating wild-type virus. Chromatographic patterns of viral DNA polymerase isolated from cells with wild-type or resistant virus were similar. However, in an in vitro assay, 50% inhibition of enzyme activity was obtained with ca. 75 and 188 ,uM aphidicolin for the wild-type and resistant DNA polymerases, respectively. Viral enzymes were much more resistant to the drug than were the cell polymerases.
of animal cells and the DNA polymerases of vaccinia and herpes viruses (27) . In an in vitro test for DNA gap-filling enzymes, the cx polymerase of the cell is much more sensitive to aphidicolin than is the vaccinia enzyme (29) .
Cell growth is also much more sensitive than vaccinia virus formation to aphidicolin (4, 22, 28) . Even aphidicolinresistant cells tolerate only drug concentrations which are below those needed to significantly reduce vaccinia virus formation (4, 6, 21) . This report supplements the initial statement on the inhibition of vaccinia virus by aphidicolin (4). The effect of the drug on virus growth and on DNA synthesis in cells with replicating viral DNA is presented. The data indicate that aphidicolin can be used to inhibit cellular DNA synthesis in infected cells without a significant reduction of viral DNA synthesis.
Virus mutants which are resistant to aphidicolin have not been described as frequently as viruses which are resistant to phosphonoacetate (PA), another compound which inhibits the DNA polymerases of herpes and vaccinia viruses (3). Variants of herpes and vaccinia viruses with decreased sensitivity to PA occur spontaneously after incubation with that drug (12, 16, 24) . Some PA mutants have been reported to be hypersensitive to aphidicolin (8) . My experience was that aphidicolin-resistant mutants did not occur at the same high frequency as do PA mutants. However, after mutagenesis with hydroxylamine, I have isolated a vaccinia virus mutant that grows at an aphidicolin concentration which reduces the titer of the wild-type progenitor more than 100-fold. Evidence for a mutation in the viral polymerase gene is that cells infected with this mutant virus produce a drugresistant DNA polymerase. Since this mutant is sensitive to PA, a mutation involving another function of the polymerase gene besides that conferring PA resistance is available.
MATERIALS AND METHODS
Drug. Aphidicolin, obtained from the Natural Products Branch, Division of Cancer Treatment, National Cancer 474 Institute, was dissolved in dimethyl sulfoxide (DMSO; Fisher Scientific Co.). One-quarter volume of glycerol was added to this solution to prepare stocks from 10 to 15 mM (3.38 to 5 .07 mg/ml) aphidicolin, which were stored at 4°C. Before use, the drug was diluted in medium, which was then filtered. Control medium without drug, containing the amount of DMSO and glycerol introduced with the aphidicolin, was also prepared by filtration.
Virus. Vaccinia virus, strain WR, was grown in HeLa cells as previously described (10) . Wild-type virus and mutants derived from this stock were also grown in BSC-1 cells, which were in confluent monolayers. Cells were infected with virus at 37°C for 1 h in a small volume of Eagle medium with 2% fetal bovine serum. The inoculating medium was replaced with a larger volume of medium with 10% serum, and incubation was continued for 26 to 72 h. Cells were then suspended in solution R (0.25% trypsin-0.02% EDTA in saline A), sedimented, suspended in medium, and frozen and thawed three times. Broken cells were treated with 125 jig of trypsin per ml for 30 min at 37°C and then diluted with 4 volumes of medium with 2.0% serum. If stocks were not used at this time, they were stored at -20°C. Thawed virus was dispersed with a vortex mixer (Scientific Products, Inc.) and by brief sonication (Heat System-Ultrasonics).
Isolation of aphidicolin-resistant vaccinia virus. Wild-type vaccinia virus was treated with hydroxylamine, as described by Condit and Motyczka (9) Virus assays. BSC-1 cells were infected with virus and incubated in medium containing aphidicolin at a concentration of 0, 80, 100, or 120 ,uM. After 24 h, the medium was replaced with fresh medium containing the same drug concentration. Cells were incubated for 48 to 72 h after infection and were stained with 0.1% crystal violet in 15% ethanol to determine the number of plaques.
To measure virus yields, BSC-1 cells were infected with 5 PFU per cell and incubated for 25 h at 37°C in medium with 10% serum and aphidicolin at a concentration of 0, 40, 80, 100, or 120 F.M. Infected cells were washed with PBS, suspended in solution R, and processed as described above. The suspension was then passed through a 21-guage needle six times, and virus titers were determined in medium without aphidicolin as described above.
Cell fractionation. HeLa cells from suspension cultures were sedimented and washed with saline containing 10 mM Tris-hydrochloride, pH 7.4. Crude nuclei were prepared by a modification of a published procedure (13) . Cells were suspended in solution N (0.1% Triton X-100, 1 mM MgCl2), held at 0°C for 10 min, and then broken in a Dounce homogenizer. Crude nuclei were sedimented, suspended in solution N, and sedimented again. The nuclei and combined supernatant (cytoplasmic) fractions were stored at -20°C.
Crude nuclei also were prepared according to the initial steps described by LaColla and Weissbach (20) . After the cells were disrupted, nuclei were sedimented from the suspension and washed with the buffer used to swell the cells. Nuclei were stored as described above. 20 mM potassium phosphate with solution G and applied to a DE-52 column (0.9 by 6 cm). After being washed with 10 ml of buffer D, proteins were eluted with 50 ml of the gradient described above. Fractions eluted from 40 to 80 mM potassium phosphate were pooled, adjusted to contain 50 mM potassium phosphate in solution G, and applied to a phosphocellulose (P 11) column (0.9 by 11 cm) which was equilibrated with 50 mM potassium phosphate and 1 mM sodium EDTA in solution G. The phosphocellulose had been treated with BSA (33) . After being washed with 20 ml of 50 mM potassium phosphate in solution G, proteins were eluted with a 90-ml gradient from 50 to 500 mM potassium phosphate in solution G. Polymerase fractions which eluted about 150 mM potassium phosphate were combined, and most of this solution was concentrated by dialysis against buffer S (100 mM potassium phosphate, 0.5 mM dithiothreitol, 50% glycerol [pH 7.5]) and stored at -20°C. A portion of the combined phosphocellulose fractions was mixed with BSA (1 mg/ml) and precipitated with a 60% saturated ammonium sulfate solution. The protein pellet was dissolved in solution G with 100 mM potassium phosphate, pH 7.5, and applied to a 50-ml column of Sephadex G-100. Fractions with polymerase activity were combined and dialyzed against buffer S. Another sample was used to inoculate a flask without aphidicolin. The resulting virus had a titer of 3.7 x 107 PFU when assayed without aphidicolin.
Several procedures were used to isolate aphidicolin-resistant mutants from the stock treated with hydroxylamine. Since the titer of mutagenized virus was low (Fig. 2) , samples of this stock were passaged once in BSC-1 cells. The procedure reported above was used to obtain the specific mutant virus described in this manuscript.
In vivo effects of aphidicolin. I estimated from Fig. 1 that 24 ,uM aphidicolin reduced the number of plaques made by wild-type vaccinia virus to one-half the number formed in drug-free medium which contained the amount of DMSO and glycerol introduced with the drug (control medium).
From Fig. 3 , I estimated that 26 ,uM drug caused 50% inhibition of wild-type virus yield. The resistance of the mutant virus to inhibition by aphidicolin is shown in Fig. 1 and 3. The resistant virus, which was isolated from a plaque formed with 80 ,uM drug present, produced yields at 100 and 120 ,uM which were at least 60 and 30%, respectively, of the value found at 80 p.M. To keep the DMSO concentration in the medium less than 1%, aphidicolin concentrations greater than 120 ,uM were not used.
The titer of the aphidicolin-resistant virus was reduced several 100-fold by the incubation of infected cells with 300 ,ug of PA per ml. Mutagenesis and aphidicolin selection did not establish PA resistance for this particular mutant.
Introduction of the drug at times up to 60 min postinfection did not greatly affect the inhibition of wild-type virus formation. BSC-1 cells were incubated with 60 ,uM aphidicolin before, at (10 PFU per cell), and after infection. In Table  1 , the virus yield is expressed as a fradtion of the yield when drug was added 60 min after infection, which was the routine procedure. The addition of drug at 7.5 h after infection did not substantially inhibit the yield. This result is consistent with the view that virus inhibition is caused by the reduction of DNA synthesis, since most viral DNA is formed by 7 h (32). The yields from aphidicolin-free infected cells treated with control medium are also presented and compared with a value for 60 min postinfection. In this experiment, there was a significant decrease in yield in the drug-free controls when the DMSO and glycerol were added before infection.
The effects of aphidicolin on virus yield were reversible. BSC-1 cells were infected with wild-type virus (10 PFU per cell). After 1 h, the inoculum was removed, medium with 60 ,uM aphidicolin or control medium was added to duplicate flasks, and incubation was continued for 3, 6, or 12 h, at which time the monolayers were washed three times with normal (drug-and DMSO-free) medium. After incubation in normal medium for 24 h from the time or reversal, the monolayers were assayed for virus. One set of flasks, incubated continuously with drug medium or control medium for 30 h, served as a positive control. Table 2 shows that removal of aphidicolin at a time up to 12 h leads to slightly larger yields than those obtained with control medium.
DNA synthesis. DNA synthesis was measured in vaccinia virus-infected HeLa cells (10 PFU per cell) and in uninfected cells processed as infected cells (mock infected). For several hours after infection, DNA synthesis in cells with replicating virus exceeds that found in uninfected cells (Fig. 4A) . The slight decrease in radioactive incorporation shown in the curve for infected cells at 260 min postinfection is atypical, because most of the data resulting from the same labeling procedure show monotonically increasing values for the incorporation throughout this period.
Four hours after mock infection, DNA synthesis in uninfected cells in medium with 1 ,uM aphidicolin was 6.4% of the value for drug-free cells (Fig. 4B ). In cells with replicating virus, incubation with 1 ,uM aphidicolin reduced DNA synthesis at 4 h postinfection to 30% of the level found in infected cells without drug (Fig. 4C) . At this time, 20 ,uM aphidicolin decreased DNA synthesis to 7% of that found in drug-free controls (Fig. 4C) , which was the same reduction as that produced by 1 ,uM drug in the uninfected cell system.
The time course of DNA synthesis in cells with replicating drug-resistant virus was similar to that found in cells with wild-type virus (Fig. 5) . At 260 min after infection, 1 ,uM aphidicolin reduced synthesis to 33% of the control (drugfree) value, which was the level of inhibition found during wild-type virus replication. However, at this time with the mutant virus, 20 ,uM drug reduced synthesis to 20% of the control value, which was about three times greater relative activity than that of the wild-type virus.
Since 1 ,uM aphidicolin reduced DNA synthesis in uninfected cells to less than 10% of the normal value, this drug concentration can be used with infected cells to suppress the contribution of cell DNA synthesis so that most of the incorporated radioactivity reflects viral DNA synthesis. This effect was confirmed by experiments in which tritiated thymidine was added to cells 1 h after infection and incubation was continued in medium with 0, 0.5, 1.0, and 5.0 F.M aphidicolin for the period of DNA synthesis. Cells were fractionated into nucleus and cytoplasm by the first procedure described above, and the amount of radioactive DNA from each fraction was determined (Fig. 6 ). In the presence of 1 ,uM drug, cytoplasmic and nuclear radioactivity levels were about 90 and 20%, respectively, of the amount found in the cytoplasm and nucleus of cells incubated without drug. Most of the nuclear radioactivity was from vaccinia virus DNA synthesis. This conclusion was derived from the results of a hybridization experiment performed by a procedure described by LaColla and Weissbach (20) . Sixty minutes after viral infection, cells were incubated with [3H]thymidine in medium without drug or with 1 ,uM aphidicolin. Crude nuclei were prepared from these cells 4 h after infection. The radioactivity associated with nuclei isolated from cells incubated with drug was 18% of that found with nuclei from drug-free cells. DNA was extracted from the nuclei and hybridized to vaccinia virus DNA immobilized on filters. The percentage of radioactivity in nuclear DNA which hybridized to the filter DNA was compared with the percentage of radioactivity in 3H-labeled DNA from purified virus which hybridized to the filter DNA. The results were that 18.3% of the virus DNA radioactivity that was incubated with the filter hybridized to viral DNA bound to the filter, whereas 22.1 and 5.6% of the radioactivity of the DNA from the nuclei of drug-treated and drug-free cells, respectively, hybridized to similar filters. Normalization of the data to the hybridization efficiency obtained with viral DNA indicates that all the radioactive nuclear DNA from drug-treated cells is viral, whereas only 30% of the radioactive nuclear DNA from drug-free cells is vaccinia DNA. Similar values were obtained at earlier times after infection. Crude nuclei, prepared 4 h after infection by another procedure (20) , from cells incubated in 1 ,uM drug also contained label DNA which hybridized to vaccinia DNA to almost the same extent as virus DNA. Controls showed that less than 0.3% of labeled HeLa cell DNA hybridized to the immobilized vaccinia DNA.
The data in Fig. 4 and 5 are presented in Table 3 , in which the radioactivity incorporated during incubation with 20 or 80 ,uM aphidicolin is expressed as a percentage of the value found in the presence of 1 ,uM drug. When the data with 20 ,uM drug were compared with those for 1 ,uM drug, there was an average of about 2.4 times greater DNA synthesis for the mutant virus than for the wild type. When the 80 ,uM results were compared with the 1 ,uM data, the mutant averaged about 4.6 times higher incorporation than the original virus.
The effects of aphidicolin on viral DNA synthesis were rapidly reversed by washing the drug from cells. Infected cells were incubated for 2 h in medium with 0 or 20 ,uM aphidicolin. The cells were washed and suspended in medium with [3H]thymidine and 1 F.M aphidicolin, which was used to suppress cell DNA synthesis. The incorporation of thymidine into acid-precipitable DNA was similar for both initial concentrations of aphidicolin (Fig. 7) .
Effect of aphidicolin on DNA polymerase. DNA synthesis in mammalian cells is reduced by the interaction of aphidicolin with DNA polymerase a (17) . To examine the effect of the drug on the DNA polymerase associated with vaccinia virus replication, I purified that enzyme from infected cells. DNA polymerase was also purified from uninfected controls. The viral polymerase was separated from host enzymes by chromatography on DEAE-cellulose, from which it eluted before the cell enzyme activity (2, 7). Figure 8 is the salt elution pattern of DNA polymerase activity from a DEAEcellulose column which had adsorbed proteins in the highspeed supernatant from an extract of HeLa cells infected with wild-type virus. The activity eluted from 40 to 90 mM potassium phosphate was not obtained by chromatography of an extract from uninfected cells, which instead had an elution pattern with a broader peak from 80 to 180 mM salt, with a maximum at 138 mM. Fractions 19 through 29, from the column with the infected cell activity (Fig. 8) , were pooled and applied to DEAE-cellulose a second time. More than 80% of the activity was eluted from the second column by the same salt concentrations that eluted the activity from the first column. Active fractions from the DEAE column used for the uninfected extract were eluted from a second DEAE column by the same salt concentrations used for the first column. Viral and host cell enzymes were purified further by phosphocellulose and Sephadex G-100 chromatography. Since DNA polymerases may be distinguished by their sensitivity to aphidicolin, several groups of DEAE column fractions were further purified by phosphocellulose chromatography. Purified, pooled fractions (Fig. 8) 18 through 24, 25 through 30, 31 through 40, 41 through 58, 59 through 70, and 71 through 80 were tested for sensitivity to 20 p.M aphidicolin in an in vitro polymerase assay. Table 4 shows that the earliest fractions were most resistant to the drug.
Extracts from cells which had replicating aphidicolinresistant virus were also purified by the above procedures. No substantial chromatographic differences were observed between wild-type and mutant virus extracts. Figure 9 does show, however, that in an in vitro assay, the viral DNA polymerase isolated from cells with mutant virus was more resistant to higher concentrations of aphidicolin than was polymerase from cells with normal virus. The 50% inhibition level was estimated at roughly 75 and 188 F.M aphidicolin for the wild-type and resistant viruses, respectively. Also shown in Fig. 9 are curves for the inhibition of a HeLa cell polymerase and calf thymus DNA polymerase a, which have 50% inhibition values estimated at 1.59 and 2.03 ,uM, respectively.
DISCUSSION
The inhibition of growth of eucaryotic cells by aphidicolin has been investigated for several years (17, 18) . Some aphidicolin-resistant mutants contain increased levels of DNA polymerase a (25, 35) or drug-resistant DNA polymerase a (21, 35) . These mutants provide evidence that the interaction of the drug with this enzyme is involved in the inhibition of cell growth.
The effects of aphidicolin on the replication of vaccinia virus have been less thoroughly investigated, although early work established that herpes simplex virus was more sensitive to the drug than was vaccinia virus (4). However, these experiments did not measure the inhibition of viral growth by plaque assay, but by scoring the fraction of tissue cultures which degenerated after infection with a particular concentration of virus obtained by serial dilution of a primary stock. With this measure of titer, 11.8 ,uM aphidicolin caused 50% inhibition of virus growth (4, 27). The strain of vaccinia virus used for this result was not identified. I estimated that 24 F.M aphidicolin caused a 50% reduction in the number of plaques of wild-type vaccinia virus, strain WR. Although my value and the 11.8 ,uM value previously reported are not disparate, the dissimilar assays and the estimates involved preclude a judgment on the difference. I estimated (Fig. 3) that 26 ,uM drug caused 50% inhibition of wild-type virus yield. This number is a more reliable measure of the effect of aphidicolin than is the value from plaque reduction experiments in which small plaques are counted.
Moss and Cooper (24) found that PA-resistant viral mutants were selected when cells were infected with wild-type virus and incubated with PA. I found no spontaneous aphidicolin-resistant mutants. Since Condit and Motyczka (9) increased the number of PA-resistant mutants of vaccinia virus by mutagenesis, I used their procedure to develop aphidicolin-resistant virus. Hydroxylamine-treated virus did not immediately form larger plaques in 80 ,uM aphidicolin. Samples of the mutagenized stock were passaged in BSC-1 cells in the presence of aphidicolin to select aphidicolinresistant virus. The mutant virus stock generated plaques with a size distribution in 80 ,uM aphidicolin which was similar to sizes produced by wild-type virus in normal medium.
The inhibition of virus growth was not significantly changed by the addition of aphidicolin before or at infection (Table 1 ). The effect on controls treated with DMSO before infection was not pursued, since no major change was seen with the drug. Cellular reactions to DMSO, including (14, 23, 34) . A water-soluble derivative of aphidicolin may soon be available (M. Suffness, personal communication), which may eliminate the need to understand the combined action of drug and solvent.
Inhibition of virus yield by aphidicolin was reversed when infected cells were washed and then incubated in drug-free medium. The reversibility implies that aphidicolin does not damage the cellular elements necessary for virus growth or alter the sequence of functions needed for virus development. In contrast to my results, Moss and Cooper (24) found that removing PA from infected cells during the period of DNA synthesis did not prevent some diminution in the yield of virus.
The inhibition of DNA synthesis in virus-infected cells by aphidicolin differs from the inhibition caused by PA. Herpes and vaccinia virus DNA synthesis are more sensitive to PA than is cell DNA synthesis (3, 19, 26) . With aphidicolin, the synthesis of cell DNA is slightly more sensitive than is the synthesis of herpes DNA and much more sensitive than the synthesis of vaccinia DNA (19, 22, 28, 29) . The consequence is that 1 FM aphidicolin will suppress most host DNA synthesis while permitting a significant amount of vaccinia DNA production. Support for this conclusion is that the amount of radioactive DNA isolated from the cytoplasm of infected cells incubated in 1 FLM drug was 90% of the amount of labeled DNA from the cytoplasm of infected cells in drugfree medium. Labeled DNA isolated from crude nuclei of infected cells cultured in 1 F.M drug was shown by hybridization data to be vaccinia DNA. This radioactivity could be attributed to contamination by cytoplasmic viral DNA or to genuine nuclear viral DNA synthesis (1, 20) . Aphidicolin concentrations up to 5 puM reduced cell DNA synthesis below the 1 ,uM level and still allowed significant viral DNA replication. Pedrali-Noy and Spadari (28) reported that 1.5 ,uM drug reduced DNA synthesis in HeLa cells to 11% of control values, and they showed increased suppression at higher concentrations. Pincus et al. (31) , who found that 0.3 p.M aphidicolin inhibited HeLa cell DNA synthesis by 97%, stated that 3 F.M aphidicolin effectively inhibits cellular DNA synthesis without affecting adenovirus 5 DNA synthesis.
Chromatography on DEAE-cellulose separates viral and cellular DNA polymerases (2) . The separation is confirmed by the increasing sensitivity of the column fractions to aphidicolin (Table 4) . Since the drug inhibits DNA polymer- ase ot, this is the enzyme which elutes after the viral enzyme. The purification process was modified by saturating the DEAE-and phosphocelluloses with BSA, which was removed by 1 M Na2HPO4 before the columns were equilibrated with a dilute solution (33) . This step increased recovery from the column but caused the polymerases to elute at lower salt concentrations than previously reported (5) .
The purification of the polymerases was limited, because extracts were prepared from small amounts of cells. Since specific activities were not available, different enzymes were adjusted to roughly equal synthetic activities before determining their sensitivity to aphidicolin. My values for the An extract from cells with replicating wild-type virus was eluted from a DEAE-cellulose column with a gradient of potassium phosphate (KP) (----). Activity is measured by acid-insoluble radioactive DNA produced in the in vitro DNA polymerase assay (0). (27) reported that aphidicolin concentrations of 2.3, 4.1, and 22 ,uM caused 50% inhibition of the in vitro activity of replicative polymerases from HeLa cells, herpes virus, and vaccinia virus, respectively. However, the values for the inhibition of HeLa, herpes, and vaccinia polymerases were also obtained with partially purified enzymes and may not reflect the true relative sensitivity. In fact, when Pedrali-Noy and Spadari (29) adjusted the condition of the in vitro assay to that found in vivo, they revised their 50% inhibition values to 0.22, 0.5, and 10 puM aphidicolin for the cell, herpes, and vaccinia enzymes, respectively, and demonstrated the effect of assay conditions. These authors showed that the last numbers are close to the in vivo 50% inhibition figures of 0.22, 0.59, and 11 ,uM for the cell, herpes virus, and vaccinia virus, respectively. However, the in vivo data they used for virus growth were those of Bucknall et al. (4), which were derived without a plaque assay.
The discrepancy between the drug inhibition values may have several sources. Although Pedrali-Noy and Spadari and I used the WR strain of vaccinia virus, I used a virus cloned from our stock. Unlike the DNA used in an earlier procedure (30) , the DNA which was the primer-template in my polymerase assay was prepared by digestion with pancreatic DNase until a maximum amount of radioactivity was incorporated in the reaction by a single preparation of DNA polymerase that was purified from uninfected HeLa cells. Since purified vaccinia virus polymerase has maximal activity between pH 8.0 and 9.2 (5), the assay contained phosphate buffer at pH 8.5 and not 7.5 (27) .
Previous studies of the interaction of aphidicolin and vaccinia virus polymerase (27, 29) have correlated the biochemical results with the effects of the drug on virus growth reported by Bucknall et al. (4) . Here, the viral and biochemical effects of the drug have been studied with the same virus preparations.
An aphidicolin-resistant virus has been developed from a hydroxylamine-treated stock. The viral DNA polymerase isolated from extracts of cells infected with the mutant virus is more resistant to the drug than is the enzyme from wildtype virus, which suggests the means of resistance. Although the aphidicolin concentrations of 75 and 188 ,uM which cause 50% inhibition of wild-type and resistant virus polymerase activities in vitro, respectively, are less than threefold different, the difference in concentrations of drug within the cell that reduce the growth of the wild-type and mutant viruses may not reflect the relative external concentrations. Also, drug inhibition of the repair of gapped DNA by polymerase may not be the best measure of the effect of aphidicolin on that enzyme in the cell. Earlier work (24) showed that a spontaneous mutant of vaccinia virus which was resistant to PA also formed a DNA polymerase which was resistant to that drug. My aphidicolin-resistant mutant is sensitive to PA. Therefore, these two drugs have generated different, altered, DNA polymerase molecules, which should lead to a more detailed understanding of the mechanism by which this important enzyme acts.
